Description
Remibrutinib, is a potent and orally active bruton tyrosine kinase (BTK) inhibitor with an IC
50 value of 1 nM. Remibrutinib inhibits BTK activity with an IC
50 value of 0.023 μM in blood. Remibrutinib has the potential for Chronic urticaria (CU) treatment.
Chemical Properties
White to off-white Solid
Uses
Remibrutinib, is a potent and orally active bruton tyrosine kinase (BTK) inhibitor with an IC50 value of 1 nM. Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood[1]. Remibrutinib has the potential for Chronic urticaria (CU) treatment[2].
References
[1] Daniela Angst, et al. Novel amino pyrimidine derivatives. Patent WO2015079417A1.
[2] Kolkhir P, et al. New treatments for chronic urticaria. Ann Allergy Asthma Immunol. 2019 Aug 23. DOI:
10.1016/j.anai.2019.08.014
